Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2025 08:00 ET | Source: Daré Bioscience, Inc.

Daré Bioscience Receives $3.6 Million in Additional Grant Funding

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising...
November 21, 2025 06:48 ET | Source: Research and Markets

U.S. Cell Culture Supplements Market Trends Analysis Report 2025-2033: Growth of Cell and Gene Therapy, and Rising Biologics and Biosimilars Production Bolster Expansion

Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "U.S. Cell Culture Supplements Market Size, Share & Trends Analysis Report by Product Type, by Application (Biopharmaceutical Manufacturing, Cell...
November 20, 2025 20:00 ET | Source: NovaBridge Biosciences

NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe...
November 20, 2025 16:05 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Crinetics announces first patient randomized in Phase 3 CAREFNDR trial of paltusotine in carcinoid syndrome
November 20, 2025 16:01 ET | Source: Inhibikase Therapeutics

Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension

Phase 3 Study initiating in First Quarter of 2026 Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON and ATLANTA, Nov. 20, 2025 (GLOBE NEWSWIRE) --...
November 20, 2025 08:15 ET | Source: Nasus Pharma, Ltd.

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

TEL AVIV, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma", “Nasus” or the "Company"), a clinical-stage pharmaceutical company focused on the development of...
November 20, 2025 08:00 ET | Source: Zapata Quantum, Inc.

Zapata Quantum Adds Financial Veteran William Klitgaard to Board as Company Aims to Relist on National Exchange

Appoints William Klitgaard to Board of Directors and Chair of Audit Committee to accelerate SEC compliance and exchange uplisting plansNames Clark Golestani Chairman of the BoardBolsters financial and...
November 20, 2025 07:30 ET | Source: Sol-Gel Technologies Ltd.

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 19, 2025 16:10 ET | Source: Regeneron Pharmaceuticals, Inc.

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing...
November 19, 2025 09:15 ET | Source: Research and Markets

Acute Bacterial Skin and Skin Structure Infection Market Analysis Report 2025-2035: Pipeline Advancements, Rising R&D Investment, and New Drug Approvals Poised to Accelerate Growth

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Acute Bacterial Skin and Skin Structure Infection Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast,...